BioSig reduces workforce again, will ‘substantially’ cut operations
2024-02-20
并购
BioSig Technologies (Nasdaq:BSGM) announced today that it terminated “a significant number of its employees.”
Shares of BSGM were up 3.1% to 64¢ apiece in mid-morning trading today following the announcement.
With this latest workforce reduction, the company says it expects to “substantially reduce business operations.” Today’s announcement marks the company’s second significant headcount cut in less than one month.
Westport, Connecticut-based BioSig announced at the end of January that it enacted a workforce reduction to reduce cash burn. The company at the time did not disclose the number of employees affected by the reduction. As of the company’s last annual report on March 30, 2023, it had 47 full-time employees.
See the full list of layoffs in medtech since mid-2022 here.
During the previous round of layoffs, BioSig announced a shift in its business model. The company develops a biomedical signal processing platform for electrocardiogram (ECG) and intra-cardiac signals. Its Pure EP system combines hardware and software to enable the real-time acquisition of raw signal data. The technology achieves this absent of unnecessary noise or interference.
The company said in January that it now wants to partner with organizations for sales distribution and clinical support of the Pure EP platform. BioSig said it aims to work with well-established electrophysiology companies and distributors with clinical staff already in the hospital setting.
It remains to be seen if that strategy remains in place following the latest layoffs.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-药物
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。